Skip to main content
. 2024 Feb 13;68(3):e01064-23. doi: 10.1128/aac.01064-23

TABLE 1.

Anti HRV-2 activities of anilinoquinazoline-based kinase inhibitor hitsa

Compound Structure     EC50 (µM)
AZ5385 graphic file with name aac.01064-23.inline001.jpg     0.5
AZ4514 graphic file with name aac.01064-23.inline002.jpg     4.4
AZ4516 graphic file with name aac.01064-23.inline003.jpg     3
AZ6252 graphic file with name aac.01064-23.inline004.jpg     1.5
AZ2538 graphic file with name aac.01064-23.inline005.jpg     1.5
AZ5756 graphic file with name aac.01064-23.inline006.jpg     1.5
AZ5765 graphic file with name aac.01064-23.inline007.jpg     1.5
AZ6610 graphic file with name aac.01064-23.inline008.jpg     1.5
AZ6636 graphic file with name aac.01064-23.inline009.jpg     1.5
AZ8146 graphic file with name aac.01064-23.inline010.jpg     4.4
AZ3426 graphic file with name aac.01064-23.inline011.jpg     5.8
AZ5719 graphic file with name aac.01064-23.inline012.jpg     4.4
Tyrphostin AG1478 graphic file with name aac.01064-23.inline013.jpg     >4b
Gefitinib graphic file with name aac.01064-23.inline014.jpg     >4b
a

Specific hits, identified by screening of the kinase inhibitor library against HRV-2, were tested for anti-HRV-2 activity in a concentration-dependent inhibition of viral cytopathic effect assay in HeLa cells. Three separate determinations were performed, and the EC50 values were calculated according to a Reed and Muench formula. Known EGFR-TKI AG1478 and gefitinib were also included for comparative purposes.

b

Lack of anti-HRV-2 activity at the highest non-cytotoxic concentration.